Researchers

MINAMI Yasunori

MINAMI Yasunori: Lecturer in Medical School

Faculty	Department of Medicine
Researchmap	https://researchmap.jp/read0076806

Education and Career

Education

- 1997 , Kindai University, Faculty of Medicine,
- 1997 , Kinki University, Faculty of Medicine,
- 2003 , Kindai University, Graduate School of Medical Sciences,

Research Activities

Research Areas

Life sciences, General surgery, pediatric surgery
Life sciences, Gastroenterology

Research Interests

Liver metastasis, 肝動脈塞栓術, ラジオ波焼灼術, 造影超音波, 肝細胞癌, Radiofrequency ablation, Contrast-enhanced sonography, Hepatocellular Carcinoma

Published Papers

Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.
Tomoko Aoki; Masatoshi Kudo; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Masakatsu Tsurusaki; Naoshi Nishida
Liver cancer 13 (1) , 56-69, Feb. 2024
Fontan術後に発症した切除不能肝細胞癌の1例
萩原智; 上嶋一臣; 西田直生志; 依田広; 三長孝輔; 南康範; 田北雅弘; 青木智子; 盛田真弘; 千品寛和; 松原卓哉; 大丸直哉; 稲村昇; 工藤正俊
肝臓 64 (11) , 567-574, Nov. 2023
Fontan術後に発症した切除不能肝細胞癌の1例
萩原智; 上嶋一臣; 西田直生志; 依田広; 三長孝輔; 南康範; 田北雅弘; 青木智子; 盛田真弘; 千品寛和; 松原卓哉; 大丸直哉; 稲村昇; 工藤正俊
肝臓 64 (11) , 567-574, Nov. 2023

肝癌診療マニュアル第2版, 肝癌の治療肝癌治療の実際内科的局所治療ラジオ波焼灼療法 RFAの適応と除外基準造影超音波下RFA. , 南康範; 工藤正俊 , 医学書院, 東京 , 2010
今日の消化器疾患治療指針第3版, 科学的根拠に基づく肝癌診療ガイドライン. , 南康範; 工藤正俊 , 医学書院, 東京 , 2010
講義録腫瘍学メジカルビュー社, 東京, 画像検査. , 南康範; 工藤正俊 , 2009

US-US overlay image fusionを用いたラジオ波焼灼術の有用性：従来治療との比較 , 南康範; 工藤正俊 , 第53回日本肝癌研究会 , 6, Jul. 2017
Precision RFAを目指して -可変型電極ができること- , 南康範 , 第53回日本肝臓学会総会 , 8, Jun. 2017
ラジオ波焼灼術後のバブルによる高エコー域を壊死部とみなして良いか？ , 南康範; 工藤正俊 , 第90回日本超音波医学会学術集会 , 25, May. 2017

Imaging Diagnosis of various HCC subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence , Yasunori Minami; Naoshi Nishida; Masatoshi Kudo , LIVER CANCER , Dec. 2022
Summary:Background. Hepatocellular carcinoma (HCC) is unique among malignancies, and its characteristics on contrast imaging modalities allow for a highly accurate diagnosis. The radiological differentiation of focal liver lesions is playing an increasingly important role, and the Liver Imaging Reporting and Data System (LI-RADS) adopts a combination of major features including arterial phase hyperenhancement (APHE) and washout pattern. Summary. Specific HCCs such as well or poorly differentiated type, subtypes including fibrolamellar or sarcomatoid and combined hepatocellular-cholangiocarcinoma does not often demonstrate APHE and washout appearance. Meanwhile, hypervascular liver metastases and hypervascular intrahepatic cholangiocarcinoma (ICC) can demonstrate APHE and washout. There are still other hypervascular malignant liver tumors (i.e., angiosarcoma, epithelioid hemangioendothelioma) and hypervascular benign liver lesions (i.e., adenoma, focal nodular hyperplasia, angiomyolipoma, flash filling hemangioma, reactive lymphoid hyperplasia, inflammatory lesion, arterioportal shunt), which need to be distinguished from HCC. When a patient has chronic liver disease, differential diagnosis of hypervascular liver lesions can be even more complicated. Meanwhile, artificial intelligence (AI) in medicine has been widely explored, and recent advancement in the field of deep learning has provided promising performance for the analysis of medical images. Especially, radiological imaging data contain diagnostic, prognostic, and predictive information which AI can extract. The AI researches have demonstrated high accuracy (over 90% accuracy) for classifying lesions with typical imaging features from some hepatic lesions. AI system has a potential to implement in clinical routine as decision support tools. However, for the differential diagnosis of many types of hypervascular liver lesions, further large-scale clinical validation still is required. Key Messages. Clinicians should be aware of the histopathological features, imaging characteristics and differential diagnoses of hypervascular liver lesions to a precise diagnosis and the more valuable treatment plan. We need to be familiar with such atypical cases to prevent a diagnostic delay, but AI based tools also need to lean a large number of typical and atypical cases.
Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis , Masatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto Nishio , JOURNAL OF CLINICAL ONCOLOGY , 40 , 4 , Feb. 2022
Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis. , Masatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto Nishio , JOURNAL OF CLINICAL ONCOLOGY , 39 , 15 , May. 2021